Supplementation in Adolescent Girls With Endometriosis (SAGE)
SAGE: Supplementation in Adolescent Girls With Endometriosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female
- Age 12 years -25 years
- Previously surgically diagnosed at Boston Children's Hospital with endometriosis
- At least 6 weeks following laparoscopy
- Minimum pain score within the 4 weeks preceding study baseline
- Must be able to swallow an empty 00 gelatin capsule at baseline
- Must be willing to stop all vitamins and nutritional supplements during trial
Exclusion Criteria:
- Concurrent chronic illnesses that affect gastrointestinal absorption of nutrients (e.g., celiac disease, IBD, cystic fibrosis)
- Vitamin D level of greater than or equal to 100 ng/ml at study baseline
- History of renal stones
- No access to text messages or email
- Pregnancy
- Non-English speaking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Vitamin D
Vitamin D3 2000 IU daily taken for 6 months
|
Nature Made Vitamin D 2000IU, 1 softgel taken daily
Other Names:
|
|
Experimental: Fish Oil
Fish Oil 1000 mg daily for 6 months
|
Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
Other Names:
|
|
Placebo Comparator: Placebo
Placebo taken daily for 6 months.
|
Placebo capsule, 2 taken daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endometriosis pain
Time Frame: 6 months
|
Measured by change in the score of the visual analog scale (VAS) from baseline to 6 months.
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life
Time Frame: 6 months
|
Measured by change in SF-36 and EPHect questionnaires from baseline to 6 months.
|
6 months
|
|
Pain medication usage
Time Frame: 6 months
|
Measured via questionnaire of medication usage from baseline to 6 months.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Stacey A Missmer, ScD, Department of Reproductive Medicine, Brigham and Women's Hospital and Harvard Medical School
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P00007860
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.